1Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe : A collaborative study of population- based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology ,2000, 54 ( 11 Suppl 5 ) :S4-9.
2Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol, 2005, 15 : 463 -471.
3Dong MJ, Peng B, Lin XT, et al. The prevalence of dementia in the People' s Republic of China: a systematic analysis of 1980- 2004 studies. Age Ageing, 2007 ,36 :619-624.
4Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer' s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol, 2008, 7:812-826.
5Smith AD. Why are drug trials in Alzheimer' s disease failing? Lancet, 2010,376 : 1466.
6Selkoe DJ. Resolving controversies on the path to Alzheimer' s therapeutics. Nat Med, 2011,17 : 1060-1065.
7Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer' s disease: recommendations from the National Institute on Aging-Alzheimer ' s Association workgroups on diagnostic guidelines for Alzheimer' s disease. Alzheimers Dement, 2011,7:280-292.
8McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer' s disease: recommendations from the National Institute on Aging-Alzheimer ' s Association workgroups on diagnostic guidelines for Alzheimer' s disease. Alzheimers Dement, 2011,7 : 263-269.
9Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology, 2007,69 : 1622-1634.
10Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl JMed, 2005,352:2379-2388.
